Dorsey & Whitney Trust CO LLC Has $1.41 Million Position in Gilead Sciences, Inc. $GILD

Dorsey & Whitney Trust CO LLC cut its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 8.3% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 12,606 shares of the biopharmaceutical company’s stock after selling 1,137 shares during the quarter. Dorsey & Whitney Trust CO LLC’s holdings in Gilead Sciences were worth $1,413,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Smallwood Wealth Investment Management LLC acquired a new stake in Gilead Sciences during the first quarter worth approximately $25,000. Goodman Advisory Group LLC acquired a new position in shares of Gilead Sciences in the first quarter valued at approximately $29,000. Colonial Trust Advisors increased its stake in shares of Gilead Sciences by 304.3% during the first quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 213 shares during the period. Core Alternative Capital increased its stake in shares of Gilead Sciences by 370.8% during the first quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 241 shares during the period. Finally, IMA Advisory Services Inc. acquired a new stake in Gilead Sciences during the 1st quarter worth approximately $39,000. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Up 0.6%

GILD stock opened at $118.73 on Thursday. The company has a market cap of $147.32 billion, a PE ratio of 23.65, a price-to-earnings-growth ratio of 0.72 and a beta of 0.33. The business has a 50-day simple moving average of $112.33 and a 200 day simple moving average of $108.78. Gilead Sciences, Inc. has a 52 week low of $74.80 and a 52 week high of $121.83. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The firm had revenue of $7.08 billion for the quarter, compared to the consensus estimate of $6.95 billion. During the same period in the prior year, the company posted $2.01 earnings per share. The business’s revenue for the quarter was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Sell-side analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, September 29th. Investors of record on Monday, September 15th will be paid a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date of this dividend is Monday, September 15th. Gilead Sciences’s dividend payout ratio (DPR) is 62.95%.

Analyst Ratings Changes

GILD has been the topic of a number of research reports. Daiwa America raised Gilead Sciences from a “hold” rating to a “strong-buy” rating in a report on Tuesday. Truist Financial raised Gilead Sciences from a “hold” rating to a “buy” rating and lifted their target price for the stock from $108.00 to $127.00 in a report on Friday, August 8th. Morgan Stanley upped their price target on shares of Gilead Sciences from $130.00 to $135.00 and gave the company an “overweight” rating in a research note on Friday, April 25th. Royal Bank Of Canada raised their price target on shares of Gilead Sciences from $96.00 to $98.00 and gave the stock a “sector perform” rating in a research report on Friday, August 8th. Finally, Needham & Company LLC upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 price objective for the company in a research note on Friday, July 25th. Three equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $115.39.

Insider Activity

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction on Friday, August 15th. The stock was sold at an average price of $118.53, for a total transaction of $296,325.00. Following the completion of the sale, the chief financial officer directly owned 160,110 shares in the company, valued at $18,977,838.30. This represents a 1.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Johanna Mercier sold 28,000 shares of the firm’s stock in a transaction on Friday, August 15th. The shares were sold at an average price of $118.53, for a total value of $3,318,840.00. Following the completion of the sale, the insider directly owned 114,168 shares in the company, valued at approximately $13,532,333.04. This represents a 19.70% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 82,000 shares of company stock valued at $9,339,230 in the last three months. Company insiders own 0.27% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.